» Articles » PMID: 35918350

Clinical Trajectories and Biomarkers for Weight Variability in Early Parkinson's Disease

Overview
Date 2022 Aug 2
PMID 35918350
Authors
Affiliations
Soon will be listed here.
Abstract

Unexplained weight changes that occur in Parkinson's disease (PD), are often neglected and remain a poorly understood non-motor feature in patients with PD. A specific 'Park-weight' phenotype with low body weight has been described, and our aim was to evaluate the clinical and prognostic trajectories and biomarkers of weight variability in PD. We evaluated body weight-related biomarkers in 405 de novo PD patients and 187 healthy controls (HC) over a 5-year follow-up period from the PPMI database. Body-weight variability was defined as intra-individual variability in body weight between visits. PD patients were categorized as weight losers, gainers, or patients with stable weight. The differential progression of motor and non-motor clinical variables between groups was explored using linear mixed-effects models. Finally, we estimated longitudinal changes in weight as a function of baseline and longitudinal striatal presynaptic dopaminergic transporter imaging. PD patients presented a greater weight variability compared to HC (p = 0.003). Patients who developed weight loss had lower CSF amyloid-beta 1-42 (p = 0.009) at baseline. In addition, patients with weight loss showed a faster cognitive decline (p = 0.001), whereas patients with weight gain showed a slower motor progression (p = 0.001), compared to patients with stable weight. Baseline right striatal denervation was a predictor of weight variability in both PD patients and HC (p < 0.001). Similarly, weight variability in PD patients was associated with the progression of right striatal denervation (p < 0.001). Weight variability and specifically weight loss are more frequent in PD compared to HC, and are associated with specific motor, non-motor and cognitive progression patterns. A greater CSF amyloid burden was present at baseline in patients with subsequent weight loss. Presynaptic dopaminergic imaging in the right striatum may serve as a predictor of future weight changes in PD and HC.

Citing Articles

Promotion of a Mediterranean Diet Alters Constipation Symptoms and Fecal Calprotectin in People with Parkinson's Disease: A Randomized Controlled Trial.

Rusch C, Beke M, Nieves Jr C, Mai V, Stiep T, Tholanikunnel T Nutrients. 2024; 16(17).

PMID: 39275262 PMC: 11396875. DOI: 10.3390/nu16172946.


Sex differences in the association between Body Mass Index and cognitive function in Parkinson disease: a cross-sectional study.

Wang Q, Bian J, Sun Y, Shi Y, Zhao Z, Zhao H Front Nutr. 2024; 11:1420225.

PMID: 39036496 PMC: 11258038. DOI: 10.3389/fnut.2024.1420225.


Gut dysbiosis impairs intestinal renewal and lipid absorption in Scarb2 deficiency-associated neurodegeneration.

Li Y, Liu X, Sun X, Li H, Wang S, Tian W Protein Cell. 2024; 15(11):818-839.

PMID: 38635907 PMC: 11528516. DOI: 10.1093/procel/pwae016.


The severity assessment of Parkinson's disease based on plasma inflammatory factors and third ventricle width by transcranial sonography.

Lu Y, Dong W, Xue X, Sun J, Yan J, Wei X CNS Neurosci Ther. 2024; 30(3):e14670.

PMID: 38459662 PMC: 10924109. DOI: 10.1111/cns.14670.


Impact of weight loss for depressive symptom in mid-stage patients with Parkinson's disease: a 4-year follow-up study.

Kurihara K, Fujioka S, Mishima T, Tsuboi Y Front Neurol. 2024; 14:1306138.

PMID: 38249744 PMC: 10796778. DOI: 10.3389/fneur.2023.1306138.


References
1.
Gao X, Chen H, Choi H, Curhan G, Schwarzschild M, Ascherio A . Diet, urate, and Parkinson's disease risk in men. Am J Epidemiol. 2008; 167(7):831-8. PMC: 2367211. DOI: 10.1093/aje/kwm385. View

2.
Ondo W, Jankovic J, Lai E, Contant C, Grossman R . Weight gain following unilateral pallidotomy in Parkinson's disease. Acta Neurol Scand. 2000; 101(2):79-84. DOI: 10.1034/j.1600-0404.2000.101002079.x. View

3.
Jankovic J, Wooten M, Van Der Linden C, Jansson B . Low body weight in Parkinson's disease. South Med J. 1992; 85(4):351-4. DOI: 10.1097/00007611-199204000-00005. View

4.
Mollenhauer B, Locascio J, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher M . α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011; 10(3):230-40. DOI: 10.1016/S1474-4422(11)70014-X. View

5.
Sharma J, Turton J . Olfaction, dyskinesia and profile of weight change in Parkinson's disease: identifying neurodegenerative phenotypes. Parkinsonism Relat Disord. 2012; 18(8):964-70. DOI: 10.1016/j.parkreldis.2012.05.004. View